Department of Pathology, Korea University Guro Hospital, Seoul, Korea
© 2016 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Study | Country | Case (n = 1,833) |
Control (n = 893) |
||
---|---|---|---|---|---|
HPV (+) | HPV (–) | HPV (+) | HPV (–) | ||
Bratthauer et al. [34] (1992) | USA | 0 | 28 | 0 | 15 |
Yu et al. [5] (1999) | China, Japan | 18 | 34 | 1 | 19 |
Damin et al. [7] (2004) | Brazil | 25 | 76 | 0 | 41 |
Tsai et al. [8] (2005) | Taiwan | 8 | 54 | 2 | 42 |
Choi et al. [9] (2007) | Korea | 8 | 115 | 0 | 31 |
de Leon et al. [11] (2009) | Mexico | 15 | 36 | 0 | 43 |
He et al. [12] (2009) | China | 24 | 16 | 1 | 19 |
Heng et al. [13] (2009) | Australia | 8 | 20 | 3 | 25 |
Mendizabal-Ruiz et al. [14] (2009) | Mexico | 3 | 64 | 0 | 40 |
Mou et al. [15] (2011) | China | 4 | 58 | 0 | 46 |
Chang et al. [35] (2012) | China | 0 | 48 | 0 | 30 |
Frega et al. [16] (2012) | Italy | 9 | 22 | 0 | 12 |
Glenn et al. [17] (2012) | Australia | 35 | 42 | 11 | 47 |
Sigaroodi et al. [18] (2012) | Iran | 15 | 43 | 1 | 40 |
Liang et al. [19] (2013) | China | 48 | 176 | 6 | 31 |
Ali et al. [23] (2014) | Iraq | 60 | 69 | 3 | 41 |
Ahangar-Oskouee et al. [24] (2014) | Iran | 22 | 43 | 0 | 65 |
Manzouri et al. [25] (2014) | Iran | 10 | 45 | 7 | 44 |
Peng et al. [26] (2014) | China | 2 | 98 | 0 | 50 |
Fu et al. [36] (2015) | China | 25 | 144 | 1 | 82 |
Vernet-Tomas et al. [33] (2015) | Spain | 0 | 76 | 0 | 2 |
Li et al. [28] (2015) | China | 3 | 184 | 0 | 92 |
Total | 342 | 1491 | 36 | 857 |
Characteristic | Criteria | No. |
---|---|---|
Age | 34–50 | 67 |
51–66 | 56 | |
Median (range) | 51.6 (23–79) | |
Operation type | Mastectomy | 108 |
Conserving operation | 15 | |
Histologic grade | Grade 1 | 27 |
Grade 2 | 41 | |
Grade 3 | 52 | |
Hormonal receptor | ER positive | 69 |
PR positive | 62 | |
HER2 positive | 52 | |
Triple negative | 25 | |
Lymph node metastasis | Positive | 54 |
Negative | 69 | |
HPV detection in cervix | Positive | 54 |
Negative | 69 | |
Histologic type | Invasive carcinoma of no special type | 103 |
Invasive lobular carcinoma | 5 | |
Microinvasive carcinoma | 1 | |
Ductal carcinoma in situ | 3 | |
Metaplastic carcinoma | 2 | |
Carcinoma with medullary feature | 2 | |
Apocrine carcinoma | 2 | |
Carcinoma with neuroendocrine feature | 1 | |
Adenoid cystic carcinoma | 1 | |
Mucinous carcinoma | 1 | |
Micropapillary carcinoma | 1 |
Case No. | Age of breast surgery (yr) | Histology of breast | Age of HPV detection at uterine cervix (yr) | Histology of uterine cervix | Method |
---|---|---|---|---|---|
15 | 50 | Invasive carcinoma of NST | 54 | NI | HC2 |
16 | 44 | Metaplastic carcinoma | 44 | LSIL | HC2 |
17 | 43 | Invasive carcinoma of NST | 44 | LSIL | HC2 |
18 | 48 | Invasive carcinoma of NST | 48 | NI | HC2 |
19 | 50 | Invasive carcinoma of NST | 50 | NI | HC2 |
20 | 46 | Invasive carcinoma of NST | 46 | LSIL | HC2 |
21 | 43 | Invasive carcinoma of NST | 41 | NI | HC2 |
22 | 49 | Invasive carcinoma of NST | 49 | NI | HC2 |
23 | 44 | Invasive carcinoma of NST | 44 | LSIL | HC2 |
24 | 63 | Invasive carcinoma of NST | 60 | Adenocarcinoma, endocervical type | HC2 |
25 | 50 | Invasive carcinoma of NST | 50 | NI | Medical record (HPV-16) |
38 | 56 | Invasive carcinoma of NST | 47 | LSIL | HC2 |
56 | 57 | Invasive carcinoma of NST | 46 | HSIL | HC2 |
Case No. | Age (yr) | Sample | Histologic type | HPV subtype |
---|---|---|---|---|
1 | 50 | FFPE | Invasive carcinoma of NST | 33 |
3 | 46 | FFPE | Invasive carcinoma of NST | 33 |
8 | 55 | FFPE | Adenoid cystic carcinoma | 40, 51, 61 |
9 | 63 | FFPE | Metaplastic carcinoma | 40, 51, 53, 61 |
17 | 23 | FFPE | Invasive carcinoma of NST | 40, 51, 53, 61 |
20 | 32 | FFPE | Invasive carcinoma of NST | 51, 53 |
30 | 47 | FFPE | Invasive carcinoma of NST | 40, 51, 58 |
39 | 44 | FFPE | Invasive carcinoma of NST | 51 |
40 | 40 | FFPE | Invasive carcinoma of NST | 33, 51, 53 |
41 | 49 | FFPE | Invasive carcinoma of NST | 51, 53 |
49 | 55 | FFPE | Invasive carcinoma of NST | 51 |
50 | 38 | FFPE | Invasive carcinoma of NST | 51 |
63 | 70 | FFPE | Invasive carcinoma of NST | 6, 51, 58 |
73 | 42 | FFPE | Invasive carcinoma of NST | 6, 40, 53 |
74 | 58 | FFPE | Invasive carcinoma of NST | 6, 51 |
75 | 54 | FFPE | Invasive carcinoma of NST | 51 |
81 | 65 | FFPE | Invasive carcinoma of NST | 6, 40 |
93 | 35 | FFPE | Invasive carcinoma of NST | 53 |
99 | 54 | FFPE | Invasive carcinoma of NST | 6 |
109 | 50 | FFPE | Invasive carcinoma of NST | 51 |
120 | 63 | FFPE | Apocrine carcinoma | 16 |
122 | 50 | FFPE | Invasive carcinoma of NST | 39 |
HPV, human papillomavirus.
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HPV, human papillomavirus.
HPV, human papillomavirus; NST, no special type; NI, in the biopsy, uterine cervical lesion was not identified; HC2, Hybrid Capture 2 (QIAGEN, Gaithersburg, MD, USA) in cytology sample; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions.
HPV, human papillomavirus; FFPE, formalin-fixed and paraffin embedded tissue; NST, no special type.